Peer-reviewed veterinary case report
Long-term remission in dogs with B-cell lymphoma after chemo
By Best, Matthew P et al.·Published in Journal of veterinary internal medicine·2023·Eastcott Referrals, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Long-term remission and survival in dogs with high-grade, B cell lymphoma treated with chemotherapy with or without sequential low-dose rate half-body irradiation.
- Species:
- dog
Plain-English summary
A group of dogs with high-grade B-cell lymphoma underwent treatment with a combination of chemotherapy and low-dose rate half-body irradiation to see if it would improve their long-term outcomes. The dogs that received both treatments had a 56% chance of remaining cancer-free for two years, while those who only received chemotherapy had no long-term remission. Additionally, 78% of the dogs treated with both therapies were still alive after two years, compared to just 11% in the chemotherapy-only group. This suggests that adding low-dose rate half-body irradiation to standard chemotherapy can significantly improve survival and remission times for dogs with this type of cancer.
People also search for: dog lymphoma treatment options · B-cell lymphoma in dogs · chemotherapy and radiation for dogs · dog cancer survival rates · long-term remission in dogs with lymphoma
Abstract
BACKGROUND: Standard of care for dogs with high-grade lymphoma, multiagent chemotherapy, achieves good initial responses but long-term remissions are infrequent; previous studies using half-body irradiation suggest improved long-term outcomes. HYPOTHESIS: The addition of low-dose rate half-body irradiation would improve outcomes in dogs with B-cell lymphoma. ANIMALS: Client-owned dogs with stage III or higher, substage a, B-cell lymphoma that achieved complete remission after 4 doses of multiagent chemotherapy. METHODS: A case-controlled design comparing 2-year remission and survival rates between dogs treated with CHOP-based chemotherapy and those treated with chemotherapy and sequential low-dose rate half-body irradiation. RESULTS: Thirty-eight dogs were enrolled with 18 included in final analysis, 9 prospectively-enrolled dogs and 9 case-matched historical controls. The irradiation cohort's 2-year disease-free rate was 56% whereas median duration exceeded the 730-day study period compared with 0% and 261 days in the chemotherapy only group. Remission duration significantly differed between cohorts (P < .01), hazard ratio 0.218 (95% CI: 0.06-0.77). The irradiation cohort's 2-year survival rate was 78% with median overall survival duration exceeding the 730 day study period compared with 11% and 286 days in the chemotherapy only group. Overall survival time significantly differed between cohorts (P < .02), hazard ratio 0.173 (95% CI: 0.03-0.839). CONCLUSIONS AND CLINICAL IMPORTANCE: The improved long-term outcome achieved by dogs administered sequential low-dose rate half-body irradiation in this study is similar to previous observational studies. Where long-term remission is sought in dogs with B-cell lymphoma low-dose rate half-body irradiation could be considered in addition to standard chemotherapy.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/37700548/